Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,049.00GBp
16 Jan 2018
Change (% chg)

-81.00 (-1.58%)
Prev Close
5,130.00
Open
5,142.00
Day's High
5,155.00
Day's Low
5,035.00
Volume
2,308,177
Avg. Vol
2,431,006
52-wk High
5,585.07
52-wk Low
4,136.50

Latest Key Developments (Source: Significant Developments)

Astrazeneca provides Tralokinumab update in severe asthma​
Wednesday, 1 Nov 2017 03:00am EDT 

Nov 1 (Reuters) - Astrazeneca Plc ::ASTRAZENECA TRALOKINUMAB UPDATE IN SEVERE ASTHMA​.ANNOUNCED TOP-LINE RESULTS OF PHASE III STRATOS 2, TROPOS TRIALS FOR TRALOKINUMAB.‍IN STRATOS 2, TRALOKINUMAB DID NOT ACHIEVE A STATISTICALLY-SIGNIFICANT REDUCTION IN ANNUAL ASTHMA EXACERBATION RATE (AAER), PRIMARY ENDPOINT.‍IN TROPOS, TRALOKINUMAB DIDN'T ACHIEVE STATISTICALLY-SIGNIFICANT REDUCTION IN ORAL CORTICOSTEROID (OCS) USE, PRIMARY ENDPOINT.‍SAFETY AND TOLERABILITY FINDINGS IN STRATOS 2 AND TROPOS WERE CONSISTENT WITH THOSE OBSERVED IN PREVIOUS TRIALS WITH TRALOKINUMAB​.  Full Article

U.S. FDA grants accelerated approval to Astrazeneca Pharmaceuticals' Calquence ‍​
Tuesday, 31 Oct 2017 02:34pm EDT 

Oct 31 (Reuters) - U.S. Food and Drug Administration::U.S. Food and Drug Administration grants accelerated approval to Astrazeneca Pharmaceuticals LP's Calquence ‍​.  Full Article

Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer
Tuesday, 31 Oct 2017 03:00am EDT 

Oct 31 (Reuters) - Incyte Corp :Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer.Incyte - ‍phase 3 trial evaluating Imfinzi and epacadostat in patients with unresectable non-small cell lung cancer is expected to begin in first-half 2018​.  Full Article

Upsher-Smith says parent co to manufacture migraine medication in Japan With AstraZeneca
Monday, 30 Oct 2017 12:19pm EDT 

Oct 30 (Reuters) - Upsher-Smith Laboratories LLC::Upsher-Smith Laboratories says co's parent Sawai Pharmaceutical entered agreement with AstraZeneca to manufacture & market migraine medication in Japan​.Upsher-Smith Laboratories​ - agreement is to ‍manufacture, market Zomig (zolmitriptan) Tablets 2.5 mg & Zomig (zolmitriptan) Rapid Melt (RM) Tablets 2.5 mg.Upsher-Smith Labs - ‍under agreement, Sawai expected to take manufacturing, marketing of Zomig​ products in Japan by mid-2018 from AstraZeneca K.K.  Full Article

Merck reports Q3 loss per share of $0.02
Friday, 27 Oct 2017 06:45am EDT 

Oct 27 (Reuters) - Merck & Co Inc :Merck announces third-quarter 2017 financial results.Q3 non-GAAP earnings per share $1.11.Q3 GAAP loss per share $0.02.Q3 sales $10.3 billion versus I/B/E/S view $10.54 billion.Q3 earnings per share view $1.03 -- Thomson Reuters I/B/E/S.‍Company narrows and raises 2017 full-year revenue range to be between $40.0 billion and $40.5 billion​.Qtrly Januvia/Janumet sales $‍1,525​ million versus $1,554 million.‍Company narrows and raises 2017 full-year GAAP EPS range to be between $1.78 and $1.84​.‍Narrows and raises 2017 full-year non-GAAP EPS range to be between $3.91 and $3.97​.‍Third-quarter pharmaceutical sales decreased 3 percent to $9.2 billion, including a 1 percent positive impact from foreign exchange​.Qtrly Keytruda sales $‍1,047​ million versus $356 million.FY2017 earnings per share view $3.87, revenue view $40.32 billion -- Thomson Reuters I/B/E/S.Qtrly remicade sales $214 ‍​ million versus $311 million.Worldwide sales for Q3 included a 1 percent positive impact from foreign exchange​.Q3 GAAP loss per share reflects $2.35 billion charge related to formation of strategic oncology collaboration with Astrazeneca​.Qtrly revenue was unfavorably impacted by about $135 million from lost sales in certain markets related to cyber-attack​.Q3 ‍sales reduced by about $240 million due to borrowing from U.S. centers for disease control & prevention pediatric vaccine stockpile of Gardasil 9​.  Full Article

US FDA approves new once-weekly BYDUREON® BCise™ injectable medicine for patients with Type-2 diabetes
Monday, 23 Oct 2017 07:00am EDT 

Oct 23 (Reuters) - AstraZeneca PLC :US FDA approves new easy-to-use, once-weekly BYDUREON® BCise™ injectable medicine for patients with Type-2 diabetes.Astrazeneca PLC - ‍BYDUREON BCise will be available for patients in US in Q1 of 2018​.  Full Article

AstraZeneca and Merck submit application for breast cancer drug in Japan
Monday, 23 Oct 2017 02:05am EDT 

By plc:‍ASTRAZENECA AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN WITH A SECOND REGULATORY SUBMISSION​.‍JAPAN NDA IS BASED ON POSITIVE RESULTS FROM PHASE III OLYMPIAD TRIAL PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE​.  Full Article

Roivant Sciences partners with AstraZeneca for drug development
Thursday, 19 Oct 2017 09:00am EDT 

Oct 19 (Reuters) - AstraZeneca Plc :Roivant Sciences says entered into a development partnership with AstraZeneca for a deprioritized investigational drug in an undisclosed indication​.Deal terms of partnership include an upfront payment, development milestones, and royalties.  Full Article

Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease
Wednesday, 18 Oct 2017 07:00am EDT 

Oct 18 (Reuters) - Fibrogen Inc :Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD).Fibrogen - ‍under terms of Fibrogen's agreement with Astrazeneca, NDA submission triggers a $15 million milestone payment, payable to co by Astrazeneca​.  Full Article

Astrazeneca says US FDA accepts regulatory submission for Lynparza
Wednesday, 18 Oct 2017 02:00am EDT 

Oct 18 (Reuters) - Astrazeneca Plc ::US FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants priority review​.  Full Article

BRIEF-Cambrex & Astrazeneca Hold Ceremony To Mark Long-Term Supply Agreement At Karlskoga, Sweden Facility

* CAMBREX & ASTRAZENECA HOLD CEREMONY TO MARK LONG-TERM SUPPLY AGREEMENT AT KARLSKOGA, SWEDEN FACILITY Source text for Eikon: Further company coverage: